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Schistosomiasis, caused by the parasitic flatworm Schistosoma mansoni and related species, is a tropical
disease that affects over 200 million people worldwide. A new approach for targeting eukaryotic parasites is to
tackle their dynamic epigenetic machinery that is necessary for the extensive phenotypic changes during the
life cycle of the parasite. Recently, we identifiedS.mansoni histone deacetylase 8 (smHDAC8) as a potential target
for antiparasitic therapy. Here, we present results on the investigations of a focused set of HDAC (histone
deacetylase) inhibitors on smHDAC8. Besides several active hydroxamates, we identified a thiol-based inhibitor
that inhibited smHDAC8 activity in themicromolar rangewith unexpected selectivity over the human isotype, which
has not been observed so far. The crystal structure of smHDAC8 complexed with the thiol derivative revealed that
the inhibitor is accommodated in the catalytic pocket, where it interacts with both the catalytic zinc ion and the
essential catalytic tyrosine (Y341) residue via its mercaptoacetamide warhead. To our knowledge, this is the first
complex crystal structure of anyHDAC inhibited by amercaptoacetamide inhibitor, and therefore, this finding offers
a rationale for further improvement. Finally, an ester prodrug of the thiol HDAC inhibitor exhibited antiparasitic
activity on cultured schistosomes in a dose-dependent manner.
© 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).Introduction
The eukaryotic trematode Schistosoma mansoni
is a human dioecious parasite that, together with other
flatworms of the same genus (Schistosoma japonicum,
Schistosoma intercalatum, Schistosoma mekongi and
Schistosoma haematobium), causes the chronic
tropical water-borne illness called schistosomiasis
or bilharzia. According to World Health Organization
statistics, over 230 million people in 77 endemic
countries require treatment for schistosomiasis, whichuthors. Published by Elsevier Ltd. This
rg/licenses/by-nc-nd/3.0/).causes 280,000 deaths yearly, in sub-Saharan Africa
alone [1]. Praziquantel is currently the only effective
drug available for the treatment of schistosomiasis.
However, its use is ineffective in case of recent in-
fections [2], its application is limited to adult worms, it
does not prevent reinfections and its mechanism of
action still remains to be determined. Additionally, with
large-scale control programs ongoing, there are
worrying reports about the effectiveness of this drug
being limited by increasing drug tolerance episodes
[3,4]. It has already been reported in literature that theis an open access article under the CC BY-NC-ND license
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Fig. 1. Structures of HDAC inhibitors and test compounds.
3443Histone deacetylase inhibition by mercaptoacetamideexpression of the efflux pump P-glycoprotein, often
involved in drug resistance, is increased in schisto-
somes as a response to praziquantel exposure [5].
The large-sized genomes of three Schistosoma
species have recently been characterized, propos-
ing a correlation between the numerous phenotypictypes that are crucial for its pathogenicity and the
gene expression profiles during all its life cycle stages
[6–9]. Epigenetic mechanisms play a central role in
programed activation or silencing of gene expression
and phenotype changes, by the means of an equilib-
rium of a large number of reversible post-translational
Table 1. In vitro inhibition results (IC50 values ± standard errors or percent inhibition at defined concentration) and ASP
docking scores (higher scores suggest more favorable interactions) on smHDAC8 and hHDAC8
Inhibitor Inhibition of smHDAC8 Inhibition of hHDAC8 ASP score smHDAC8 ASP score hHDAC8
SAHA 1.6 ± 0.2 μM 0.4 ± 0.1 μM 39.65 42.29
SAHA-COOH 1.9 ± 0.4 μM 0.4 ± 0.2 μM 33.36 37.38
ST80 0.8 ± 0.2 μM 0.3 ± 0.04 μM 38.58 46.67
Crebinostat 0.9 ± 0.3 μM 0.3 ± 0.02 μM 43.76 48.05
HHA 2.5 ± 0.4 μM 0.6 ± 0.1 μM 26.34 23.88
SAA n.i. at 100 μM n.i. at 100 μM 27.77 28.30
1a 50 ± 4 μM 200 ± 37 μM 27.71 26.96
2 n.i. at 100 μM n.i. at 100 μM 34.15 29.92
M344 2.4 ± 2.0 μM 2.9 ± 1.5 μM 38.73 39.93
3 2.9 ± 0.3 μM 0.6 ± 0.04 μM 39.39 39.70
4 12 ± 2 μM 0.6 ± 0.1 μM 35.22 32.94
5 1.4 ± 0.2 μM 0.1 ± 0.02 μM 37.90 48.47
6 42.3% at
100 μM and
13.1% at 1 μM
1.1 ± 0.4 μM 28.11 25.83
PCI-34051 0.4 ± 0.1 μM 26 ± 8 nM 40.94 47.63
3444 Histone deacetylase inhibition by mercaptoacetamidemodifications that constitute the so-called “histone
code” [10]. Modifications such as acetylation, methyl-
ation, phosphorylation, ubiquitinylation, SUMOylation
or glycosylation on certain amino acid residues in
histones or non-histone proteins are responsible
for changes in the structure and stability of histone/
histone and histone/DNA interactions, modulating
gene expression and recruiting other proteins [11,12].
The balance of acetylation and deacetylation of histone
lysine residues is catalyzed by histone acetyltransfer-
ases and HDACs (histone deacetylases), respectively.
The ε-amino residues of lysines in histone tails, when
deacetylated, are able to compact the chromatin struc-
ture, usually resulting in a reduced accessibility of
promoters for transcription factors and consequently
inhibition of transcription [13,14]. This well-studied
modification also occurs in S. mansoni, as previously
described [15].
The family of zinc-dependent HDACs in human
consists of 11 members that can be divided into three
classes. In the parasite S. mansoni, three members of
class I deacetylases are known, which represent
orthologues of mammalian HDAC1, HDAC3 and
HDAC8 [16]. HDAC8 from S. mansoni [S. mansoni
histone deacetylase 8 (smHDAC8)] contains significant
alterations of the catalytic domain as compared to
orthologous enzymes of other organisms. While human
HDAC8 (hHDAC8) shows the lowest level of expres-
sion of the four class I HDACs in human, in
schistosomes, transcripts of smHDAC8areexpressed
at higher levels than smHDAC3 and smHDAC1 during
all life cycle stages, underlining its specific and vital
functions in the parasite life cycle. All these peculiar-
ities of smHDAC8 make it a promising target for the
development of new species-selective drugs.
In previous work, we have validated smHDAC8 as
a potential drug target andwere able to solve its crystal
structure, both in the apo-form and in complexes with
different hydroxamate inhibitors [17]. In this latter study,
the known HDAC inhibitors suberoylanilide hydroxa-mic acid (SAHA; Vorinostat) and M344 [18] (Fig. 1)
were shown to inhibit smHDAC8 in the low-micromolar
region that constituted the starting point for the work
described in the present paper.Results and Discussion
Focused library screening against smHDAC8
Here, in a focused library screening approach, we
tested analogues of M344 and SAHA and represen-
tative HDAC inhibitors from in-house libraries and
the literature for inhibition of smHDAC8. Generally,
most HDAC inhibitors are represented by a general
structure (see Fig. 1) that comprises a so-called war-
head that usually complexes the zinc ion, a spacer that
mimics the lysinemethylene side chain and a so-called
capping group that extends to the rim of the active-
site tunnel. As analogues of SAHA, we used a newly
synthesized carboxylic acid derivative (SAHA-COOH),
the HDAC6-selective inhibitor ST80 [19], crebinostat
[20] and hexanoylhydroxamate (HHA) that does not
have an aromatic capping group. Additionally, we
prepared three compounds that bear a variation of the
warhead in SAHA. These are the carboxylic acid of
SAHA (suberanilic acid, SAA [21]), a mercaptoaceta-
mide analogue (1a) [22–25] and a newly synthesized
epoxy ketone (2). The thiol 1a and the epoxide 2
are simplifications of the well-known natural product
inhibitors romidepsin [26,27] and trapoxin [28], re-
spectively. For cellular testing of 1a, we prepared the
known thioester prodrug 1b that liberates the active
principle in cells [22,23]. As congeners of M344, we
included a benzoic acid derivative (3) [18] and its
1,4-cyclohexylene analogue (4) [29]. As S. mansoni
has also been shown to be susceptible to induction of
apoptosis by sirtuin inhibitors [30], we also synthe-
sized a new dual sirtuin/HDAC inhibitor (5) with a
Table 2. Data collection and refinement statistics
smHDAC8/1a
Data collection
Space group P1
Cell dimensions
a, b, c (Å) 70.8, 70.8, 98.0
α, β, γ (°) 77.8, 75.5, 85.4
Resolution (Å) 50.0–2.3
Rsym 0.106 (0.340)
a
I/σ(I) 15.2 (4.2)
Completeness (%) 96.3 (93.8)
Redundancy 3.8 (3.8)
Refinement
Resolution (Å) 32.0–2.3
No. of reflections 79,759
R-work/R-free 0.191/0.233
No. of atoms
Protein 13,012
Ligands/ions 185
Water 451
B-factors (Å2)
Protein 26.5
Ligands/ions 39.6
Water 25.9
RMSD
Bond lengths (Å) 0.01
Bond angles (°) 1.02
Ramachandran plot statistics (%)
Favored 98
Allowed 2
Outliers 0
a Values in parentheses are for the highest-resolution shell
(2.34–2.30 Å).
3445Histone deacetylase inhibition by mercaptoacetamidepartial structure of the sirtuin inhibitor Ro 31-8220 [31].
As established inhibitors of hHDAC8, we selected a
derivative of dichlorohomophenyl-D-alanine (6) [32]
and PCI-34051 [33]. We then tested the inhibition of
smHDAC8 and hHDAC8 for all these compounds.
We used a commercially available homogenous fluo-
rescence assay [Fluor de Lys(R)-HDAC8] with an
acetylated tetrapeptide sequence derived from p53
(Arg-His-AcLys-AcLys-Fluorophor) as substrate. The
results are displayed in Table 1.
The results of the in vitro assays revealed that all
inhibitors with a hydroxamic acid warhead are inhibi-
tors of both the S. mansoni and the human enzyme in
the low-micromolar range or even below with a slight
selectivity for the human isoform over the schistoso-
mial HDAC8. The nature of the capping group seems
to be of little importance in our set, at least for affinity to
the human enzyme. Even the simple alkyl derivative
HHA is in the submicromolar range. For analogues of
M344, increased steric bulk in the spacer (compounds
3 and 4) decreased activity, whereas PCI-34051 with
an indole spacer is nevertheless in the submicromolar
range. Obviously, in more rigid molecules, the relative
position of hydroxamate and capping group is of great
importance for affinity. Exchange of the hydroxamate
warhead generally leads to a substantial loss of ac-
tivity in smHDAC8 and, with the exception of 6, also forhHDAC8. However, while the carboxylic acid SAA and
the epoxy ketone 2 are completely inactive, the thiol
1a retained activity specifically for smHDAC8 around
50 μM.
The smHDAC8 preparation that was used in the
assays contains DTT, which is a well-known reducing
agent able to break disulfide bonds.We also prepared
a DTT-free preparation of smHDAC8 and tested the
inhibition of the thiol inhibitor. Compound 1a showed
a reduced inhibitionof smHDAC8withoutDTT (157.8 ±
18.6 μM; data not shown), which suggests that the
dithiol probably serves to prevent disulfide formation or
further oxidation of the thiol inhibitor.
Crystal structure of smHDAC8 in complex with
the mercaptoacetamide inhibitor 1a
To rationalize the inhibition of smHDAC8 by the
mercaptoacetamide 1a, we determined the crystal
structure of smHDAC8 in complex with this com-
pound. Crystallographic data of the complex at 2.3 Å
resolution were collected. The refined model of this
complex has low R-factors and shows good refine-
ment statistics (Table 2). In general, no dramatic con-
formational changes were observed in smHDAC8
upon binding of 1a when compared to the native
smHDAC8 and inhibited forms of smHDAC8 struc-
tures described recently [17]. Most of the residues
could be built in density, except for a few disordered
loops. Themercaptoacetamide inhibitor binds to each
monomer in the asymmetric unit of the crystal with full
occupancy and its electron density was perfectly
defined and unambiguously interpretable as shown in
Fig. 2.
As noted above, 1a is an HDAC inhibitor com-
posed of a mercaptoacetamide warhead, a hydropho-
bic flexible linker domain and a hydrophobic capping
group. The crystal structure of the smHDAC8/1a
complex reveals that the inhibitor is accommodated
in the catalytic pocket, where it interacts with both the
catalytic zinc ion and Y341 via its mercaptoacetamide
group (Figs. 2 and 3).
To our knowledge, after the hHDAC8/largazole
complex structure [34], this is only the second
structure of an HDAC complex, where a sulfur–Zn2+
coordination is observed and the first one for any
mercaptoacetamide. The zinc ion coordination geom-
etry in the smHDAC8/1a structure is tetrahedral and
similar to that observed in the hHDAC8/largazole
structure, with ligand–Zn2+–ligand angles ranging
from 100° to 119° (Fig. 3). TheS–Zn2+ distance ranges
between 2.2 and 2.3 Å across all monomers (A to D) in
the asymmetric unit. The optimal tetrahedral zinc
coordination likely provides a significant contribution
to smHDAC8–1a affinity.
However, and in contrast to largazole, the mercap-
toacetamide head of the inhibitor makes a further
contactwith anactive-site residue, namely, the catalytic
tyrosine Y341 (Fig. 2). Specifically, Y341 adopts the
Fig. 2. Structural insight into the smHDAC8 inhibition by the mercaptoacetamide inhibitor 1a.(a) Representation of 1a
and calculated simulated annealing omit map contoured at 1.2 σ around the inhibitor observed in the crystal structure of the
smHDAC8/1a complex.(b) Ribbon diagram of the overall structure of smHDAC8 together with the catalytic zinc ion (orange
sphere) and the bound inhibitor represented in space filling.(c) Close-up views of the active site of smHDAC8 (shown as
sticks) with bound inhibitor 1a shown as (i) ribbon, (ii) surface view and (iii) side cut-away surface view.(d) Schematic
representation of the interactions formed by the mercaptoacetamide inhibitor with the smHDAC8 active-site zinc ion and
residues.
3446 Histone deacetylase inhibition by mercaptoacetamideflipped-in conformation, as seen in hydroxamate-
inhibited smHDAC8 structures for example [17], that
facilitates an interaction of its hydroxyl group with the
carbonyl atom of the mercaptoacetamide group
(Fig. 2). Interestingly, upon 1a binding, smHDAC8
F151 fully occupies an unusual flipped-in conforma-
tion [17] and, together with F216, forms the hydro-
phobic tunnel that accommodates the slightly kinked
aliphatic linker of the inhibitor. ThemeasuredC–C–S–
Zn dihedral angle in the X-ray structure of largazole/
HDAC8 is on average 92.4° (88.1 and 96.6 for
monomer A and monomer B, respectively). For the
thiol 1a/smHDAC8structure,weobserved anaveragevalue of 12.9° (28.4, 26.8, −17.0 and 13.5 for the
individual monomers). The difference in the dihedral
angles can beexplainedbyadditional hydrogen bonds
that are observedwith the protein. In case of largazole,
the thiol makes an additional hydrogen bond with
Tyr306, whereas in case of 1a, the carboxamide
makes the hydrogen bond with Tyr341.
Thus, the binding of the mercaptoacetamide group
to the catalytic zinc results in a different positioning
of the hydrophobic linker and capping group that 1a
has in common with SAHA. However, both inhibitors
bind quite differently into the smHDAC8 active site.
This might explain why on one hand an increase in
Fig. 3. Tetrahedral coordination of the zinc ion bound in the active site in smHDAC8/1a and hHDAC8/largazole complexes.
(a) Overall structure of S. mansoni HDAC8 together with the catalytic zinc ion (orange sphere) and the bound inhibitor 1a
represented in space filling. The inset shows close-up view of the smHDAC8 active site. Residues involved in the zinc
coordination are drawn with sticks. The carbon atoms of proteins side chains are in gray, whereas the carbon atoms of 1a are in
cyan. Yellow broken lines represent the coordination of the zinc ion by protein residues and the inhibitor.(b) Overall structure of
hHDAC8 together with the catalytic zinc ion (orange sphere) and the bound largazole inhibitor represented in space filling. The
inset shows close-up view of the hHDAC8 active site. Residues involved in the zinc coordination are drawn with sticks. The
carbon atomsof proteins side chains are in gray, whereas the carbonatoms of 1aare in brown. Yellowbroken line represents the
coordination of the zinc ion by protein residues and largazole.
3447Histone deacetylase inhibition by mercaptoacetamidethe IC50 value of 1a compared to SAHA is observed,
but the selectivity is shifted toward theparasite enzyme.
Further improvements of 1a are necessary to increaseFig. 4. Observed correlation between in vitro pIC50 values
hHDAC8 (b) computational models.the potency of inhibitors with a mercaptoacetamide
warhead while maintaining its favorable selectivity as
compared to SAHA.and calculated ASP docking scores for smHDAC8 (a) and
Fig. 5. Docking poses observed for the most active compound PCI-34051 (colored cyan) at the smHDAC8 (a) and
hHDAC8 binding pocket (b). Only interacting amino acids are displayed for clarity. Residues coordinating the zinc ion are
colored orange and hydrogen bonds/coordination to the zinc ion is indicated by the green lines (distances are given in
angstroms).
3448 Histone deacetylase inhibition by mercaptoacetamideDocking studies and rationalization of structure–
activity relationships
To predict the binding mode of the tested com-
pounds and to rationalize the structure–activity rela-
tionships, we carried out amolecular docking study for
S. mansoni and hHDAC8. For both enzymes, crystal
structures that were used to find the right docking
setup are available (see Experimental Procedures for
details). Using this setup, we were able to reproduce
the known crystal structures of S. mansoni HDAC8 in
complex with SAHA resp. M344 and the thiol 1a from
this study (RMSDvalues below 1 Å). The results show
that the docking and scoring models (using the ASP
score) can be used to discriminate between active and
inactive/weakly active compounds (Table 1), and in
general, a correlation between the docking scores and
pIC50 values was observed (Fig. 4). All inactive
compounds and compounds active above 15 μM
received docking scores below 29, except compound
2. Active compounds, usually hydroxamates, received
favorable docking scores above 32, except HHA and
compound 6 in case of hHDAC8. All hydroxamates
show coordination to Zn2+ with the hydroxamic acid
group and fit nicely into the pocket of both smHDAC8
and hHDAC8. However, we also observed that the
scoring functions (including ASP score) have prob-
lems for correctly ranking the non-hydroxamates.
Beside the problem of correctly scoring different
zinc-binding groups, we suppose that the known
protein flexibility of HDACs might be responsible for
the incorrect ranking of some compounds (2, 6 and
HHA). For example, in case of compound 6, the
conformational changeof hHDAC8upon binding of this
ligand is observed in its X-ray structure (PDB ID: 3SFH)
[30]. The dichlorophenyl group fits into the putative
acetate release channel, which is openedmainly by themovement of the Trp141 side chain in hHDAC8. This
conformational change is not possible in smHDAC8
due to the surrounding residues. The movement of
Trp140 in smHDAC8 (corresponding to Trp141 in
hHDAC8) might be prevented by Phe21, which
corresponds to Ile34 in hHDAC8. Consequently, the
α-amino-ketone group of 6 cannot reach Zn2+ inside
the binding pocket, which explains the weak activity on
smHDAC8.
The docking pose of PCI-34051, the most active
compound tested on hHDAC8 and smHDAC8, shows
that the hydroxamic acid coordinates Zn2+ and the
aromatic indole interactswith several aromatic residues
in both enzymes (Fig. 5). In complex with hHDAC8, the
methoxyphenyl group is embedded in a hydrophobic
pocket formed by Phe152, Pro273, Met274 and
Tyr306. This pocket is more polar in smHDAC8
where Met274 is substituted to His292, which might
explain the weaker enzymatic inhibition and the lower
calculated scores. Also for the other active hydroxa-
mates, such as crebinostat and ST80 for example, an
interaction with this hydrophobic side pocket in both
enzymes is observed (see Fig. S1a–d).
Antiparasitic activity
Because it is well known that, for cellular activity in
sulfur-based HDAC inhibitors, thiol esters should be
employed rather than the free thiols, the ester 1b was
tested for anti-schistosomal activity. The inhibitor 1b
decreases the viability of cultured schistosomula in a
dose- and time-dependent manner in the range 10–
50 μM (Fig. 6). Moreover, similar to pan-HDAC
inhibitors [15], induction of apoptosis at 20 and 50 μM
1b was shown using TUNEL (terminal deoxynucleo-
tide transferase dUTP nick end labeling) staining
(Fig. 7).
Fig. 6. Decrease in viability in cultured schistosomula
treated for up to 5 days with increasing concentrations of
1b. Dead and dying larvae are dark and opaque and
present granular aspects and tegumental damage. Results
are expressed as mean percentage of surviving larvae
(±SEM, three independent experiments).
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Among a small focused library of HDAC inhibitors
that were tested for inhibition of S. mansoni HDAC8
as potential antiparasitic agents, a thiol analogue
(1a) of the hydroxamate inhibitor SAHA showed
decreased potency but increased selectivity for
smHDAC8 over hHDAC8. The HDAC8 reference
inhibitor PCI-34051 shows potent activity against
smHDAC8, suggesting indoles as an optimized
spacer motif for affinity to the parasite enzyme. We
were able to solve the structure of the thiol inhibitor
bound to smHDAC8 as a first example of a
co-complex of a mercaptoacetamide with an HDAC
of any origin. Interestingly, just by exchange of the
zinc-coordinating warhead, a completely different
bindingmode of 1a as compared toSAHA is observed
[17], although spacer and capping group are the
same. This can be realized due to the flexibility of the
spacer and the flexible nature of key phenylalanine
residues that shape the acetyl lysine tunnel in
smHDAC8. Additionally, we have shown antiparasitic
activity of the thiol ester prodrug 1b on cultured
schistosomes.Fig. 7. TUNEL staining for apoptosis in cultured schistosom
control, (b) 20 μM 1b and (c) 50 μM 1b. Background stain
Positively TUNEL labeled schistosomula are red. The intensi
larvae, increased with the dose of inhibitor used. Size bars insmHDAC8 has been validated as a unique thera-
peutic target by transcript invalidation using RNA
interference before, but we cannot rule out the pos-
sibility that the antiparasitic effect of inhibitor 1b, at
least in part, may have been due to the inhibition of
other Schistosoma HDACs. In literature, usually
hydroxamate warheads are given priority in studies
on HDAC inhibitors but there is also continuing
interest in sulfur-based warheads [35,36]. Especially
interesting is the fact that, in a cellular model of neuro-
protection, mercaptoacetamides were active while
structurally similar hydroxamateswere not [37]. Taken
together, our results serve as a rational basis for the
further structure-guided optimization of HDAC inhib-
itors for both potency and species selectivity as
potential therapeutics against schistosomiasis.Experimental Procedures
Chemistry and inhibitors
The inhibitors PCI-34051 and SAHA were pur-
chased from Selleck Chemicals; SAA, at Biozol; and
HHA, at Chemical Book. Synthetic procedures and
spectral characterization data are presented in detail in
the supplemental material. All chemicals were pur-
chased from Sigma, Aldrich or Fluka and used without
further purification. Starting materials, reagents and
analytical-grade solvents were obtained from com-
mercial sources. T3P 50% weight in THF and 50%
weight in DMF were kindly donated by Archimica
(Frankfurt, Germany). Chromatographic separations
were performed on silica gel (15–40 mesh; Merck)
using flash methodology. Reaction progress was
monitored by analytical thin-layer chromatography on
pre-coated silica gel (Kieselgel 60 F254) plates, and
spots were detected by UV light (λ = 254 nm). Melting
points of the final target HDAC inhibitors were de-
termined by the open capillary method on a Stuart-
Scientific SMP3 electrothermal apparatus and are
uncorrected. 1H NMR spectra were recorded in the
indicated deuterated solvents on a BrukerAvanceula induced by different concentrations of 1b. (a) DMSO
ing was performed using 4′,6-diamidino-2-phenylindole.
ty of labeling, as well as the number of positively stained
all three panels represent 100 μm.
3450 Histone deacetylase inhibition by mercaptoacetamideDRX 400-MHz spectrometer, and 13C NMR, on a
Varian 100 MHz. Chemical shifts (δ) are expressed in
parts per million, and coupling constants (J) are in
hertz. The following abbreviations are used: bs (broad
singlet), s (singlet), d (doublet), dd (double doublet), t
(triplet), dt (double triplet), m (multiplet); signals due to
OH and NH protons were located by deuterium
exchange with D2O. EI and CI mass spectra were
measured with a TSQ700 mass spectrometer (Ther-
moelectron). ESI and PCI mass spectra were
recorded with a LCQ-Advantage mass spectrometer.
In all cases, spectroscopic data are in agreement with
known compounds and assigned structures. HPLC
purity determinations were performed on a JASCO
HPLC system under isocratic conditions, using
a PhenomenexSynergi Hydro RP-C18 column
(250 mm × 4.6 mm, 4 μm particle size). Elution was
performed using 0.05% of TFA in H2O/ACN 60/40
(v/v), at room temperature. The purity of all tested
compounds was ≥98%, as measured by HPLC.
Injection volumes were 2 μL, flow rate was 0.5 mL/min
and detection was performed with UV (λ = 254 nm).
In vitro HDAC inhibition assay, enzymes
The activity of compounds prepared for this study
was evaluated using an HDAC enzyme inhibition
homogenous fluorescence assay. The HDAC activ-
ity assay was performed using a commercial HDAC8
Fluorimetric Drug Discovery Kit [Fluor de Lys(R)-H-
DAC8, BML-KI178] according to the manufacturer's
instructions. The enzyme was incubated for 90 min
at 37 °C, with a substrate concentration of 50 μM
and increasing concentrations of inhibitors. Fluores-
cence intensity was measured in a plate reader
(BMG Polarstar) with excitation wavelength set at
390 nm and emission detection set at 460 nm.
The gene coding for the smHDAC8 protein was
introduced into a pnEA/tH expression vector [38], and
the smHDAC8 protein was produced according to the
same protocol as described previously [17]. Briefly,
overexpression was carried out in Escherichia coli
BL21(DE3) cells in Terrific Broth medium. Induction
was performed at 37 °C by adding 0.5 mM final
isopropyl-1-thio-β-D-galactopyranoside (Euromedex),
in the presence of 100 μM ZnCl2. Harvested bacteria
were resuspended in lysis buffer [50 mM KCl and
10 mM Tris–HCl (pH 8.0)] and lysed under high
pressure (18,000 psi) in a Microfluidizer Processor
M-110EH (Microfluidics). The lysate was clarified by
ultracentrifugation (40,000 rpm; Ti45 Beckman) for
1 h. The supernatant was loaded onto Talon metal
affinity resin (Clontech) pre-equilibrated with the lysis
buffer. The His-tagged smHDAC8 protein was re-
leased from the Talon resin by thrombin treatment and
subsequently loaded onto a 1-mL HiTrap Q FF (GE
Healthcare) column pre-equilibrated with the lysis
buffer. The protein was eluted by a linear gradient of
KCl (50 mM to 1 M KCl) and then loaded onto HiLoad16/60 Superdex 200 gel-filtration column (Amersham
Bioscience) equilibrated in 50 mM KCl, 10 mM Tris–
HCl (pH 8.0) and 2 mM DTT when required (see the
text).
In vitro sirtuin inhibition, enzymes
Human Sirt1 (amino acids 133–747), human Sirt2
(amino acids 25–389) and human Sirt3 (amino acids
101–399) were recombinantly expressed and puri-
fied as described before [39]. IC50 values for 5 were
determined using a homogeneous fluorescence-
based assay (see Table S1) [40]. Sirt1–Sirt3 were
incubatedwith5at various concentrations [4 h, 37 °C,
10.5 μM ZMAL, 5% (v/v) DMSO, 500 μM NAD+,
25 mMTris, 137 mMNaCl, 2.7 mMKCl, 1 mMMgCl2,
pH 8.0, 60 μL]. Deacetylation was then stopped by
addition of a trypsin solution [5.5 U/μL trypsin, 12 mM
nicotinamide, 6.6% (v/v) DMSO, 50 mM Tris, 50 mM
NaCl, pH 8.0, 60 μL], incubated (20 min, 37 °C) before
fluorescence intensity was measured (λEx = 390 nm,
λEm = 460 nm; BMG Polarstar). Inhibition rates were
determined in reference to a control with DMSO. Sub-
strate conversionwas adjusted to 10–30%. IC50 values
were calculated with GraphPad Prism 5.0.
Crystallization and X-ray data collection
Co-crystallization of smHDAC8 together with 1awas
performed using hanging-drop vapor diffusion tech-
nique. The smHDAC8/1a complex was formed by
incubating the smHDAC8 protein (2 mg/mL) with 1a
(5 mM resuspended in dimethylformamide) at 4 °C for
1 h. Diffraction-quality crystals were obtained at 17 °C
after 3–4 days by mixing equal volumes of the
smHDAC8/1a complexes with reservoir solution com-
posed of 21% polyethylene glycol 3350 (Fluka) and
0.2 M Na+/K+ L-tartrate. Crystals used for X-ray data
collection were briefly transferred in reservoir solution
supplemented with 22% glycerol and flash-frozen in
liquid nitrogen. Crystallographic data were collected at
100 K on in-houseRigakuMicroMax-007HF generator
fitted with Osmic VariMax HF confocal optics and
Saturn 944 CCD detector.
Structure determination, model building and
refinement
Crystallographic data were processed and scaled
using HKL2000 [41]. Since the crystals of the
smHDAC8/1a complex belonged to the same space
group (P1) and had the same unit cell as native
smHDAC8 crystals [17], only rigid-body refinement
was used to adapt to the slight differences in unit cell
constants using Phenix [42].
The initial model was refined through several cycles
of manual building using Coot [43] and automated
refinement with Phenix [42] and Buster [44]. The final
model was validated using tools provided in Coot [43]
3451Histone deacetylase inhibition by mercaptoacetamideand MolProbity [45]. The model has low R-factors and
good refinement statistics (Table 2).
Computational methods
The recently solved crystal structures of S. mansoni
HDAC8 with SAHA (PDB ID: 4BZ6 [17]) was used for
the docking studies. For hHDAC8, several X-ray
structures have been reported in complex with various
inhibitors [46]. We took the crystal structure 2V5X.pdb
[47] for thedocking studies since it gave thebest results
in cross-docking of a large library of published and
in-house HDAC8 inhibitors (data not shown). Struc-
tures were prepared with Schrödinger's Protein Prep-
aration Wizard [48]. Hydrogen atoms were added and
the hydrogen bond network was optimized subse-
quently. The protonation states were predicted using
the PROPKA tool within the Schrödinger program at
pH 7.0. Two conserved water molecules located near
Zn2+ were considered during the protein preparation
process. Four models with different hydration of the
binding pocket were generated for each protein. They
were subjected to restrained energyminimization using
the force field OPLS2005 (RMSD of the atom
displacement for terminating the minimization 0.3 Å).
Ligands were prepared in MOE [49] (version
2012.10; Chemical Computing Group, Montreal, Can-
ada). Conformational search was performed using the
Low Mode MD sampling with a minimum RMSD
between the conformations of 0.5 Å to obtain realistic
starting conformations for the flexible ligands.
Molecular docking was carried out on a Linux
cluster using Glide (Schrödinger Inc, New York, USA)
[48] in the standard precision mode. In addition, the
docking program Gold 5.2 [50] was used. Finally, the
docking complexes were rescored using several
scoring functions (GlideSP, GoldScore, ChemScore,
ASP, Chem-PLP). The best reproducibility of
smHDAC8 and hHDAC8 inhibitor complexes was ob-
served using Glide docking and rescoring with ASP
score.
Antischistosomal effects of smHDAC8 inhibitors
A Puerto Rican strain of S. mansoni maintained in
the laboratory using the intermediate snail host
Biomphalaria glabrata and the golden hamster Meso-
cricetus auratus as definitive hostwasused.Cercariae
were released from infected snails and harvested on
ice as described previously [51], and schistosomula
were obtained in vitro by mechanical transformation
[52]. The effects of smHDAC8 inhibitors on the viability
of schistosomula maintained in culture were assayed
exactly as previously described [30]. Briefly, 2000
schistosomula were incubated at 37 °C in a humid
atmosphere containing 5% CO2 during 5 days in
6-well plates containing 2 mL of M199 medium
(Invitrogen) kept at pH 7.4 with Hepes (10 mM) and
supplemented with penicillin (50 U/mL), streptomycin(50 μg/mL), gentamycin (15 μg/mL) and rifampicin
(60 μg/mL) and 10% fetal calf serum (Gibco) with
different concentrations of inhibitors dissolved in
DMSO. Culture medium was refreshed daily. Parasite
mortality was assessed by eye each day using three
criteria: absence of motility, tegument defects and
granular appearance. A minimum of 300 larvae was
observed for each condition, and the ratio of dead
larvae to total larvae was calculated. Two different
assays were performed for each condition and three
independent biological replicates (different batches of
schistosomula) were carried out.
To detect DNA strand breaks in inhibitor-treated
schistosomula, we performed the TUNEL method with
the In Situ Cell Death Detection Kit, TMR red (Roche),
exactly as previously described [30]. Briefly, 2000
schistosomulawere treated or not for 48 hwith inhibitor
as above. Culture medium was removed and the
schistosomula were centrifuged (1000 rpm, 2 min),
washed three times in phosphate-buffered saline and
then fixed in 2% formaldehyde for 60 min. After a
further wash in phosphate-buffered saline, perme-
abilization solution (0.1% Triton X-100, 0.1% sodium
citrate) was added for 10 min on ice. Labeling of
schistosomula with 4′,6-diamidino-2-phenylindole and
TMR red dUTP was performed according to the
manufacturer's instructions and TUNEL-positive
parasites were observed by fluorescence using an
AxioImager Z1-Apotome microscope (Zeiss).
Accession numbers
The atomic coordinates and structure factors of
the smHDAC8/1a complex have been deposited in
the Protein Data Bank under the accession code
4cqf. The PDB file of the complex is available as
supplemental material to this paper.Acknowledgments
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